← Back to Search

ZD 1839 + Chemotherapy for Lung Cancer

Phase 3

Waitlist Available

Research Sponsored by AstraZeneca

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologically proven non-small cell lung cancer Stage III disease that is not curable with surgery or radiotherapy OR Stage IV disease chemotherapy naive

Hepatic: ALT or AST no greater than 2.5 times upper limit of normal (ULN) (no greater than 5 times ULN if liver metastasis present)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will compare the effectiveness of combination chemotherapy with or without ZD 1839 in treating patients who have stage III or stage IV non-small cell lung cancer.

Who is the study for?

This trial is for adults over 18 with non-small cell lung cancer that hasn't been treated with chemo yet. They should have a certain level of kidney, liver, and blood health, no severe heart or lung conditions, and not be pregnant or nursing. Participants must use contraception if they can have children.Check my eligibility

What is being tested?

The study is testing the effectiveness of ZD 1839 (a drug that may block tumor growth) combined with chemotherapy versus chemotherapy alone in patients with advanced stage III (not curable by surgery/radiotherapy) or stage IV non-small cell lung cancer.See study design

What are the potential side effects?

ZD 1839 might cause side effects like diarrhea and skin reactions. Chemotherapy can lead to hair loss, nausea, fatigue, increased risk of infection due to low blood counts, and other organ-related issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My lung cancer is at an advanced stage and hasn't been treated with chemotherapy.

Select...

My liver tests are within the required range, even with liver metastasis.

Select...

My kidney function, measured by creatinine, is within normal limits.

Select...

My heart condition is stable and under control.

Select...

My lung condition is stable and not severe.

Select...

I am 18 years old or older.

Select...

I can take care of myself and perform daily activities.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 7Eligibility criteria met

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor

4,259 Previous Clinical Trials

288,593,902 Total Patients Enrolled

Ron StaugarrdStudy ChairAstraZeneca

1 Previous Clinical Trials

Media Library

Combination Chemotherapy Clinical Trial Eligibility Overview. Trial Name: NCT00006049 — Phase 3

Lung Cancer Clinical Trial 2023: Combination Chemotherapy Highlights & Side Effects. Trial Name: NCT00006049 — Phase 3

Combination Chemotherapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT00006049 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new patients being accepted into this research project at this time?

"This information is available on clinicaltrials.gov. The trial in question was last active 5/1/2000- 12/18/2013, and is not currently looking for participants. There are 2098 other trials that patients can sign up for."

Answered by AI

Does this medication have the FDA's OK?

"The safety of this intervention falls on the higher end of the spectrum because it is a Phase 3 trial. This indicates that while there may be some data supporting efficacy, there is multiple rounds of data affirming its safety."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

2000. "ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00006049.

All > Lung > Sclc